Sun Pharmaceutical Industries Limited
SUNPHARMA
주식 순위
#532
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
주가
$19.17
시가총액
$46.00B
변동 (1일)
-0.34%
변동 (1년)
-0.18%
국가
IN
거래 Sun Pharmaceutical Industries Limited (SUNPHARMA)
카테고리
Healthcare
Sun Pharmaceutical Industries Limited (SUNPHARMA)의 매출
Jun 2026 기준 매출 TTM: $6.61B
Sun Pharmaceutical Industries Limited의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $6.61B입니다. 2024년에 회사는 $5.82B의 수익을 올렸으며 이는 2023년의 $5.34B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Sun Pharmaceutical Industries Limited의 수익 기록 (2004 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $6.61B | 7.55% |
| 2025 | $6.15B | 5.70% |
| 2024 | $5.82B | 8.91% |
| 2023 | $5.34B | 4.87% |
| 2022 | $5.09B | 11.28% |
| 2021 | $4.58B | 4.98% |
| 2020 | $4.36B | 4.14% |
| 2019 | $4.19B | 3.17% |
| 2018 | $4.06B | -15.97% |
| 2017 | $4.83B | 13.79% |
| 2016 | $4.24B | -3.35% |
| 2015 | $4.39B | 63.63% |
| 2014 | $2.68B | 29.00% |
| 2013 | $2.08B | 31.80% |
| 2012 | $1.58B | 22.91% |
| 2011 | $1.28B | 47.70% |
| 2010 | $869.23M | 3.29% |
| 2009 | $841.54M | 0.33% |
| 2008 | $838.79M | 70.54% |
| 2007 | $491.84M | 33.83% |
| 2006 | $367.50M | 33.92% |
| 2005 | $274.42M | 20.98% |
| 2004 | $226.82M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
